That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Stock index futures jump on reports of Senate breakthrough to end shutdown. Taiwan Semi's October revenue rises 17% YoY, ...

Having lost the battle for Metsera, the Danish company continues its fight in the world of anti-obesity drugs, competing with ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

During his remarks to military leaders at Marine Corps Base Quantico several weeks ago, Donald Trump ranted about the Gulf of Mexico (or the Gulf of America, according to him). He falsely claimed that ...

Metsera's lead pipeline asset is MET-097i, a GLP-1 receptor agonist designed for once-monthly injection. Novo's weight-loss drugs Wegovy and Eli Lilly's Zepbound and Mounjaro require weekly injections ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...

Novo Nordisk and Pfizer's multibillion-dollar fight over who gets to buy an anti-obesity biotech has morphed into a narrative ...